Evidence map›Paper›PMID 40041909›Full record

ArticleActa pharmaceutica Sinica. B2025

Discovery of a novel thiophene carboxamide analogue as a highly potent and selective sphingomyelin synthase 2 inhibitor for dry eye disease therapy.

Jintong Yang, Yiteng Lu, Kexin Hu, Xinchen Zhang, Wei Wang, Deyong Ye, Mingguang Mo, Xin Xiao, Xichen Wan, Yuqing Wu and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jintong YangSchool of Pharmacy, Fudan University, Shanghai 201203, China.
Yiteng LuDepartment of Ophthalmology, Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai 200031, China.
Kexin HuInstitute of Precision Medicine, the Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200125, China.
Xinchen ZhangSchool of Pharmacy, Fudan University, Shanghai 201203, China.
Wei WangSchool of Pharmacy, Fudan University, Shanghai 201203, China.
Deyong YeSchool of Pharmacy, Fudan University, Shanghai 201203, China.
Mingguang MoSchool of Pharmacy, Fudan University, Shanghai 201203, China.
Xin XiaoSchool of Pharmacy, Fudan University, Shanghai 201203, China.
Xichen WanDepartment of Ophthalmology, Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai 200031, China.
Yuqing WuDepartment of Ophthalmology, Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai 200031, China.
Shuxian ZhangInstitute of Metabolism and Integrative Biology, Fudan University, Shanghai 200438, China.
He HuangInstitute of Metabolism and Integrative Biology, Fudan University, Shanghai 200438, China.
Zhibei QuSchool of Pharmacy, Fudan University, Shanghai 201203, China.
Yimin HuSchool of Pharmacy, Fudan University, Shanghai 201203, China.
Yu CaoInstitute of Precision Medicine, the Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200125, China.
Jiaxu HongDepartment of Ophthalmology, Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai 200031, China.
Lu ZhouSchool of Pharmacy, Fudan University, Shanghai 201203, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dry eye disease (DED) is a prevalent and intractable ocular disease induced by a variety of causes. Elevated sphingomyelin (SM) levels and pro-inflammatory cytokines were detected on the ocular surface of DED patients, particularly in the meibomian glands. Sphingomyelin synthase 2 (SMS2), one of the proteins involved in SM synthesis, would light a novel way of developing a DED therapy strategy. Herein, we report the design and optimization of a series of novel thiophene carboxamide derivatives to afford

Indexed as

Dry eye diseaseHuman corneal epithelial cellsMeibomian glandsSMS2 inhibitorSphingomyelinSphingomyelin synthase 2Thiophene carboxamideTumor necrosis factor receptor 1

Identifiers

PMID40041909
PMCPMC11873635

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.